94 results about "Transplant rejection" patented technology

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

The present invention concerns the use of a molecule chosen from a globin, a globin protomer or an extracellular hemoglobin of Annelids, for treating and / or preventing at least one complement-activation associated disease, preferably ischemia / reperfusion injury and / or transplant rejection.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The invention belongs to the technical field of biomedicine, and particularly relates to a diagnostic marker for lung transplantation rejection and application of the diagnostic marker. The invention discloses one or more of OIT3, CAMP, USP4, IPO9 and PON1 as markers for diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the markers. The invention discloses that the OIT3 can be used as a diagnosis and treatment target of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the OIT3; the lung transplantation rejection reaction can be prevented and / or treated through the OIT inhibitor.

The present invention relates to a gelatin-coated acellular dermal tissue and a use thereof. More specifically, the present invention relates to: an acellular dermal tissue in which gelatin derived from human skin tissue is crosslinked on the surface of the acellular dermal tissue; and a use thereof for treating skin damage. The gelatin-coated acellular dermal tissue according to the present invention has predetermined physical properties so as to provide ease of handling, and also eliminates toxicity and transplant rejection responses, and thus can be effectively used for treating patients with skin tissue damage.

Described herein are kits, compositions, and methods for detecting porcine antigens in biological samples. The kit comprises a support, anti-porcine antibodies coupled to the support, and instructions for preparing lysates from a porcine donor source and contacting the lysates with the anti-porcine antibodies. The kit may be for use in determining the risk of transplant rejection in a human subject receiving or being considered for receiving a transplant from the porcine donor.

To provide Akt3 modulators and compounds and pharmaceutical compositions for treating diseases by modulation of Akt3 signaling.SOLUTION: A compound of Formula Ib or Ic, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound for treating a disease in a subject in need thereof, A pharmaceutical composition wherein the treatment comprises administering to a subject an effective amount of the compound; optionally wherein the disease is selected from the group consisting of neurodegenerative diseases, cachexia, eating disorders, obesity, complications of obesity, inflammatory diseases, virally-induced inflammatory reactions, Gulf War Syndrome, tuberous sclerosis, retinitis pigmentosa, graft rejection, cancer, autoimmune diseases, ischemic tissue injury, traumatic tissue injury and combinations thereof.SELECTED DRAWING: Figure 6

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

Provided is a modified regulatory T cell capable of recognizing cells of the liver, capable of treating and / or preventing transplant rejection or immune-mediated damage, and capable of promoting regeneration of cells of the liver.SOLUTION: The present invention provides engineered regulatory T cells (Tregs) comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain that specifically binds to the asialoglycoprotein receptor (ASGR). The invention also provides a method of promoting liver tissue repair and / or regeneration in a subject, said method comprising administering to said subject a modified Treg comprising a CAR, or a pharmaceutical composition comprising said modified Treg, wherein said CAR comprises a liver-specific antigen recognition domain.SELECTED DRAWING: None

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

This disclosure relates to anti-human CD154 antibodies with modified effector function. This disclosure also relates to the use of these anti-human CD154 antibodies in treating conditions associated with CD154 activation, such as transplant rejection, inflammatory conditions and disease, dysfunctional immune responses associated with viral infections and diseases, autoimmune conditions and disease, allergic conditions, atherosclerotic conditions, or neurodegenerative conditions and diseases. It also relates to the use of these anti-human CD154 antibodies in inducing central tolerance and hematopoietic chimerism in transplant patients.

The invention relates to the technical field of medicines, and discloses camphorsulfonate, a crystal form, a composition and a preparation method and application thereof, and the camphorsulfonate is AXL kinase inhibition camphorsulfonate. The crystal form of the camphorsulfonate is substantially pure. The basically pure AXL kinase inhibition camphorsulfonate crystal form disclosed by the invention has good performance and high bioavailability; therefore, the compound can be used for preparing medicines for treating and / or preventing proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, virus infectious diseases, heart failure, cardiovascular diseases or other diseases of mammals.

The application relates to the diagnosis and treatment of diseases, including cancer, chronic infectious diseases, autoimmune diseases, inflammatory disorders, as well as the prevention of transplant rejection. The invention provides, and involves the use of, antibody molecules that bind CD28 in a non super-agonistic manner and which also bind to CTLA-4. The antibody molecules may form part of a bispecific molecule which binds e.g. a tumor associated antigen or a further T cell antigen, such as CD3.

The disclosure relates to compositions and methods useful for gene therapy and for the prevention and treatment of cardiac allograft rejection in the transplant setting.

This invention relates to the use of IL-6 inhibitors for preventing or inhibiting lung transplantation rejection in a subject. In particular, this invention relates to methods of treatment of antibody mediated rejection (AMR) of a lung transplant in a subject in need thereof comprising a combination therapy of (i) administration to the subject of an antibody or fragment which is capable of inhibiting human IL-6; and (ii) administration to the subject of an immunosuppressive therapy, wherein the immunosuppressive therapy does not comprise any antibody or fragment thereof which is capable of inhibiting human IL-6.

The invention relates to the technical field of medicines, and discloses a salt, a crystal form and a composition of an AXL kinase inhibitor as well as a preparation method and application of the salt, the crystal form and the composition of the AXL kinase inhibitor, and the salt is hydrochloride, sulfate, phosphate, mesylate, benzene sulfonate, p-toluenesulfonate, camphorsulfonate, maleate and oxalate. The crystalline form of the AXL kinase inhibitor salt is substantially pure. The basically pure AXL kinase inhibitor crystal form disclosed by the invention has good performance and high bioavailability; therefore, the compound can be used for preparing medicines for treating and / or preventing proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, virus infectious diseases, heart failure, cardiovascular diseases or other diseases of mammals.

To provide compositions comprising components of multi-component CALs or CARs, and to provide methods for treating autoimmune diseases and the like.SOLUTION: A composition is provided comprising a TCR recognition domain and one or both of (a) an intracellular signaling domain and (b) a first-type protein interaction domain. Further provided is a method for treating or preventing autoimmune disease, transplant rejection, or graft-versus-host disease.SELECTED DRAWING: Figure 10

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

The invention relates to the technical field of medicines, and particularly discloses an engineered drug-loaded macrophage for resisting transplant rejection. PD-L1 is overexpressed on the surface of a cell membrane of the engineered drug-loaded macrophage, and the engineered drug-loaded macrophage internally contains nanoparticles encapsulated with rapamycin. Due to the biological characteristic that the macrophages can respond to inflammation signals, the engineered drug-loaded macrophages can be efficiently recruited to rejection reaction parts by chemotactic factors of transplantation parts, and the engineered drug-loaded macrophages can penetrate a tissue barrier as an active carrier, respond to external stimulation to exocytosis and release nanoparticles encapsulated with rapamycin after reaching a target position, and can be used for preparing a drug carrier. Local precise delivery of PD-L1 and rapamycin is realized, and immunosuppression toxicity of systemic administration is reduced.

Provided herein are microfluidic arrays and miR panels useful in the identification of human subjects experiencing or at risk of experiencing an acute heart allograft rejection. Further provided are methods of identifying human subjects experiencing or at risk of experiencing an acute heart allograft rejection, including Acute Cellular Rejection (ACR) or antibody-mediated rejection (AMR). Further provided are system, apparatus, device, method and / or computer program product aspects, and / or combinations and sub-combinations thereof, for detecting an allograft rejection.

Clinical detection or diagnosis of transplant rejection currently utilizes various methods that rely on qualitative rather than quantitative data, or quantitative data that has low sensitivity and / or has a high rate of operator error. Provided herein are methods for identifying kidney transplant rejection in patents that is automated and consistent for the user. Further described herein are cut-offs for transplant biomarkers that relate to renal transplantation stability or rejection.

The application discloses an application of niclosamide in treating organ transplant rejection. The application discloses that niclosamide can specifically interfere with the TMEM16F-CLIC1 interaction, thereby inhibiting the uptake of donor EVs by DCs, prolonging the survival time of a heart transplant by interfering with the 'costume change' of recipient DCs and inhibiting T cell activation, and indicating a new use of niclosamide in transplant immunoregulation.

The invention provides a heteroaryl compound, a preparation method of the heteroaryl compound and application of the heteroaryl compound in medicine. Specifically, the invention provides a heteroaryl compound as shown in a general formula (I), a preparation method of the heteroaryl compound, a pharmaceutical composition containing the heteroaryl compound and application of the heteroaryl compound as a therapeutic agent, especially application of the heteroaryl compound as a Bruton's tyrosine kinase (BTK) inhibitor and application of the heteroaryl compound in treatment and / or prevention of various diseases related to excessive BTK activity. Including cancer, autoimmune diseases, inflammatory diseases, allergic diseases, allergic reactions, respiratory diseases, cardiovascular diseases, viral infections, transplant rejection, metabolic / endocrine dysfunction, and neurological disorders.

Disclosed is a compound of Formula (I), or a stereoisomer, tautomer, or salt or solvate thereof, wherein all variables are as defined herein. The compounds modulate the activity of farnesoid X receptor (FXR), e.g., as agonists. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating diseases, disorders, or conditions associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

The present disclosure relates to transgenic animals with nuclear genomes comprising knockouts of both alleles of an SLA-DQ gene and / or an SLA-DR gene. The disclosure provides transgenic pigs, transplant products from the transgenic pigs and xenotransplantation methods utilizing the transplant products for treatment of transplant rejection, especially in humans.

The invention provides a kidney transplantation rejection reaction serum polypeptide detection device and method, and the method comprises the steps: obtaining a kidney transplantation serum sample, and extracting a polypeptide characteristic signal group of the serum sample from a polypeptide mass spectrum of the serum sample in a preset mass-to-charge ratio range; the polypeptide characteristic signal group comprises three characteristic polypeptide peak signals corresponding to different protein fragments, and further determining the mass-to-charge ratio of each protein fragment and the relative intensity value of each characteristic polypeptide peak in the polypeptide characteristic signal group; carrying out fusion judgment on the rejection risk of the serum sample according to the mass-to-charge ratio of each protein fragment and the relative intensity value of each characteristic polypeptide peak in the polypeptide characteristic signal group to obtain a risk index representing the rejection state in the serum sample; and comparing the risk index with a rejection risk threshold value of the serum sample so as to make multi-level judgment on the rejection risk level to which the serum sample belongs. Based on the scheme, rejection reaction monitoring based on kidney transplantation serum polypeptide fingerprints can be realized.

Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as pancreatic transplant recipients, pancreatic and kidney transplant recipients, and simultaneous pancreatic and kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA) or each an independent assessment of the mRNA transcript level as well as an independent assessment of the dd-cfDNA. Genes that correlate with pancreatic transplant rejection in simultaneous pancreatic and kidney transplant recipients are also disclosed.

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.

The application discloses an indazole derivative or a pharmaceutical salt thereof and application. The application finds a new indazole derivative, which has an inhibiting function on ROCK kinase, can be used as a ROCK kinase inhibitor, and has a novel structure type, and can be used as a potential therapeutic drug for various diseases, such as inflammatory diseases, autoimmune diseases, fibrotic diseases, transplant rejection, diseases related to excessive secretion of IL-17, IL-21 and / or IL-23, eye diseases, cardiovascular and cerebrovascular diseases, tumor metastasis, central nervous system diseases, diabetic nephropathy and skin diseases, and the like.

The present disclosure relates to transgenic animals with nuclear genomes comprising knockouts of both alleles of an SLA-DQ gene and / or an SLA-DR gene. The disclosure provides transgenic pigs, transplant products from the transgenic pigs and xenotransplantation methods utilizing the transplant products for treatment of transplant rejection, especially in humans.